

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
7 April 2005 (07.04.2005)

PCT

(10) International Publication Number  
**WO 2005/030778 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 491/04,**  
A61K 31/438, A61P 25/00

(21) International Application Number:  
PCT/GB2004/004116

(22) International Filing Date:  
24 September 2004 (24.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/505,731 25 September 2003 (25.09.2003) US

(71) Applicant (for all designated States except MG, US): AS-  
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant (for MG only): ASTRAZENECA UK LIM-  
ITED [GB/GB]; 15 Stanhope Gate, London Greater London  
W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DORFF, Peter**  
[US/US]; AstraZeneca R & D Wilmington, 1800 Concord  
Pike, Wilmington, Delaware 19850-5437 (US). **GOR-**  
**DON, John** [US/US]; AstraZeneca R & D Wilmington,  
1800 Concord Pike, Wilmington, Delaware 19850-5437  
(US). **HEYS, John, Richard** [US/US]; AstraZeneca R &  
D Wilmington, 1800 Concord Pike, Wilmington, Delaware  
19850-5437 (US). **KEITH, Richard, A** [US/US]; As-  
traZeneca R & D Wilmington, 1800 Concord Pike,  
Wilmington, Delaware 19850-5437 (US). **MCCARTHY,**  
**Dennis, J** [US/US]; AstraZeneca R & D Wilmington,  
1800 Concord Pike, Wilmington, Delaware 19850-5437  
(US). **PHILLIPS, Eflion** [GB/US]; AstraZeneca R

& D Wilmington, 1800 Concord Pike, Wilmington,  
Delaware 19850-5437 (US). **SMITH, Mark, A** [US/US];  
AstraZeneca R & D Wilmington, 1800 Concord Pike,  
Wilmington, Delaware 19850-5437 (US).

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; As-  
traZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: LIGANDS



(I)

(57) Abstract: A radioactive compound having the formula (I), where R<sup>1</sup> and Ar are as defined in the specification, pharmaceuti-  
cally-acceptable salts thereof, compositions containing such compounds and uses thereof in diagnosis of conditions wherein the  $\alpha_2$   
nicotinic receptor is involved.